Md Saifur Rahman Khan
PhD
Saifur R. Khan is a postdoctoral fellow at the University of Toronto. His current research focuses
on discovering prognostic and novel drug targets for type 2 diabetes mellitus (T2DM) using artificial
intelligence (AI)-assisted big data analytics and systems biology, followed by genetic models of diabetes, molecular biology, and cell biology.
His studies unveiled the role of sphingolipids in T2DM pathophysiology.
He designed a novel bioinformatic platform to map standalone metabolomics on to GWAS database to identify genetic predisposition for altered metabolomics in any disease.
He identified two prognostics with ~92% AUC for predicting future T2D.
In his PhD at the University of Alberta, he identified three pharmacological functions of isoniazid, a first-line antituberculosis drug, using pharmacogenomics and biochemical studies. He proposed a new mode of action of isoniazid, which opens a way to utilize isoniazid in drug-resistance TB. Previously, he was a senior scientist at Incepta Pharmaceuticals Ltd, Bangladesh.